These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 17880568)

  • 1. Levodopa-induced ocular dyskinesia in Parkinson's disease.
    Grötzsch H; Sztajzel R; Burkhard PR
    Eur J Neurol; 2007 Oct; 14(10):1124-8. PubMed ID: 17880568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease.
    LeWitt PA
    Mov Disord; 1998 Jul; 13(4):731-4. PubMed ID: 9686783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa-induced ocular dyskinesias in Parkinson's disease.
    Linazasoro G; Van Blercom N; Lasa A; Indakoetxea B; Ruiz J
    Mov Disord; 2002 Jan; 17(1):186-7. PubMed ID: 11835460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.
    Zhang YH; Tang BS; Song CY; Xu Q; Lou MX; Liu ZH; Yu RH; Yan XX; Guo JF
    Neurosci Lett; 2013 Nov; 556():109-12. PubMed ID: 24135335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.
    Luquin MR; Scipioni O; Vaamonde J; Gershanik O; Obeso JA
    Mov Disord; 1992; 7(2):117-24. PubMed ID: 1350058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term variability in amplitude and motor topography of whole-body involuntary movements in Parkinson's disease dyskinesias and in Huntington's chorea.
    Fenney A; Jog MS; Duval C
    Clin Neurol Neurosurg; 2008 Feb; 110(2):160-7. PubMed ID: 18063471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa-induced dyskinesia in Parkinson's disease.
    Brotchie JM; Lee J; Venderova K
    J Neural Transm (Vienna); 2005 Mar; 112(3):359-91. PubMed ID: 15614429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal bidirectional plasticity-like effects in Parkinson's disease.
    Huang YZ; Rothwell JC; Lu CS; Chuang WL; Chen RS
    Brain; 2011 Aug; 134(Pt 8):2312-20. PubMed ID: 21742734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis of dyskinesias in Parkinson's disease.
    Mouradian MM; Heuser IJ; Baronti F; Fabbrini G; Juncos JL; Chase TN
    Ann Neurol; 1989 May; 25(5):523-6. PubMed ID: 2774496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias.
    Morgante F; Espay AJ; Gunraj C; Lang AE; Chen R
    Brain; 2006 Apr; 129(Pt 4):1059-69. PubMed ID: 16476674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Movement patterns of peak-dose levodopa-induced dyskinesias in patients with Parkinson's disease.
    Gour J; Edwards R; Lemieux S; Ghassemi M; Jog M; Duval C
    Brain Res Bull; 2007 Sep; 74(1-3):66-74. PubMed ID: 17683791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa, motor fluctuations and dyskinesia in Parkinson's disease.
    Müller T; Russ H
    Expert Opin Pharmacother; 2006 Sep; 7(13):1715-30. PubMed ID: 16925499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.
    Koller W; Guarnieri M; Hubble J; Rabinowicz AL; Silver D
    J Neural Transm (Vienna); 2005 Feb; 112(2):221-30. PubMed ID: 15503197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
    Fox SH; Chuang R; Brotchie JM
    Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
    Stathis P; Konitsiotis S; Tagaris G; Peterson D;
    Mov Disord; 2011 Feb; 26(2):264-70. PubMed ID: 21412833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Motor complications of Parkinson's disease.
    Martignoni E; Riboldazzi G; Calandrella D; Riva N
    Neurol Sci; 2003 May; 24 Suppl 1():S27-9. PubMed ID: 12774208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prefrontal alterations in Parkinson's disease with levodopa-induced dyskinesia during fMRI motor task.
    Cerasa A; Pugliese P; Messina D; Morelli M; Gioia MC; Salsone M; Novellino F; Nicoletti G; Arabia G; Quattrone A
    Mov Disord; 2012 Mar; 27(3):364-71. PubMed ID: 22076870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dyskinesia-induced postural instability in Parkinson's disease.
    Armand S; Landis T; Sztajzel R; Burkhard PR
    Parkinsonism Relat Disord; 2009 Jun; 15(5):359-64. PubMed ID: 18851925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia.
    Suh DC; Pahwa R; Mallya U
    J Neurol Sci; 2012 Aug; 319(1-2):24-31. PubMed ID: 22664154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.